Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Cunningham, J M ^a   Cicek, M S ^a   Larson, N B ^a   Davila, J ^a   Wang, C ^a   Larson, M C ^a   Song, H ^b   Dicks, E M ^b   Harrington, P ^b   Wick, M ^a   Winterhoff, B J ^a   Hamidi, H ^c   Konecny, G E ^c   Chien, J ^d   Bibikova, M ^e   Fan, J B ^e   Kalli, K R ^a   Lindor, N M ^f   Fridley, B L ^g   Pharoah, P P D ^b   Goode, E L ^a   more..

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^e ILLUMINA INC   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; DNA BINDING PROTEIN; RAD51C PROTEIN, HUMAN;

ARTICLE; CLASSIFICATION; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENETICS; HOMOLOGOUS RECOMBINATION; HUMAN; MIDDLE AGED; MORTALITY; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; OVARY TUMOR;

BASE SEQUENCE; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA METHYLATION; DNA-BINDING PROTEINS; FEMALE; HOMOLOGOUS RECOMBINATION; HUMANS; MIDDLE AGED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 84896780582     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04026     Document Type: Article

References (47)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA: A Cancer Journal for Clinicians 63, 11-30 (2013).
2. Pharoah, P. D. & Ponder, B. A. The genetics of ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 16, 449-468 (2002).
3. Miki, Y. et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71 (1994).
4. Wooster, R. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792 (1995).
5. Aarnio, M., Mecklin, J. P., Aaltonen, L. A., Nystrom-Lahti, M. & Jarvinen, H. J. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer. 64, 430-433 (1995).
6. Meindl, A. et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 42, 410-414 (2010).
7. Meindl, A., Ditsch, N., Kast, K., Rhiem, K. & Schmutzler, R. K. Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int. 108, 323-330 (2011).
8. Loveday, C. et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet. 43, 879-882 (2011).
9. Bojesen, S. E. et al.Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 45, 371-384 (2013).
10. Permuth-Wey, J. et al. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun. 4, 1627 (2013).
11. Pharoah, P. D. et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 45, 362-370 (2013).
12. Shen, H. et al. Epigenetic analysis leads to identification of HNF1B as a subtypespecific susceptibility gene for ovarian cancer. Nat Commun. 4, 1628 (2013).
13. Bolton, K. L. et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 42, 880-884 (2010).
14. Goode, E. L. et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 42, 874-879 (2010).
15. Song, H. et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 41, 996-1000 (2009).
16. Ramus, S. J. & Gayther, S. A. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 3, 138-150 (2009).
17. Berchuck, A. et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res. 4, 2433-2437 (1998).
18. Foster, K. A. et al. Somatic and germlinemutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res. 56, 3622-3625 (1996).
19. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
20. Baldwin, R. L. et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60, 5329-5333 (2000).
21. Bol, G. M. et al. Methylation profiles of hereditary and sporadic ovarian cancer. Histopathology 57, 363-370 (2010).
22. Bianco, T., Chenevix-Trench, G., Walsh, D. C., Cooper, J. E. & Dobrovic, A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21, 147-151 (2000).
23. Demsky, R. et al. Keeping it simple: Genetics referrals for all invasive serous ovarian cancers. Gynecol Oncol. 130, 329-333 (2013).
24. Pharoah, P. D., Easton, D. F., Stockton, D. L., Gayther, S. & Ponder, B. A. Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res. 59, 868-871 (1999).
25. Liu, J. et al. Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet. 205, 34-41 (2012).
26. Bolton, K. L. et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. Jama 307, 382-390 (2012).
27. Alsop, K. et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 30, 2654-2663 (2012).
28. Tutt, A. & Ashworth, A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med. 8, 571-576 (2002).
29. Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 28, 2512-2519 (2010).
30. Tinker, A. V. & Gelmon, K. The role of PARP inhibitors in the treatment of ovarian carcinomas. Curr Pharm Des. 18, 3770-3774 (2012).
31. Walsh, T. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U.S.A. 108, 18032-18037 (2011).
32. Huang, J. -W., Wang, Y., Dhillon, K. K., Calses, P., Villegas, E., Mitchell, P. S., Tewari,M., Kemp, C. J. & Tanaguchi, T. Sytematic screen identifies miRNAs that target RAD51C and RAD51D to enhance chemotherapy. Mol Cancer Res. 11, 1-10 (2013).
33. Kobel, M. et al. Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. Cancer Epidemiol Biomarkers Prev. 22, 1677-1686 (2013).
34. Turner, N., Tutt, A.& Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 4, 814-819 (2004).
35. Tan, D. S. et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 26, 5530-5536 (2008).
36. Clague, J. et al. RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS One 6, e25632 (2011).
37. Coulet, F. et al.Germline RAD51C mutations in ovarian cancer susceptibility. Clin Genet. 83, 332-336 (2013).
38. Hansmann, T. et al. Constitutive promoter methylation of BRCA1 and RAD51C in patients with familial ovarian cancer and early-onset sporadic breast cancer. Hum Mol Genet. 21, 4669-4679 (2012).
39. Loveday, C. et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet. 44, 475-476 (2012).
40. Abkevich, V. et al. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Br J Cancer 107, 1776-1782 (2012).
41. McLaughlin, J. R. et al. Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2. J Natl Cancer Inst. 105, 141-148 (2013).
42. Rigakos, G. & Razis, E. BRCAness: Finding the achilles heel in ovarian cancer. Oncologist 17, 956-962 (2012).
43. Goode, E. L. et al. Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev. 20, 1638-1648 (2011).
44. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
45. Larson, D. E. et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics 28, 311-317 (2012).
46. Asmann, Y. W. et al. TREAT: a bioinformatics tool for variant annotations and visualizations in targeted and exome sequencing data. Bioinformatics 28, 277-278 (2012).
47. Cicek, M. S. et al. Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K1 channel. Hum Mol Genet. 22, 3038-3047(2013).